title: The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women.
abstract: BACKGROUND
  Two sequential hormone replacement regimens, containing either estradiol valerate plus medroxyprogesterone acetate (E2V/MPA) or conjugated estrogens plus medrogestone (CE/MED), were compared with respect to effects on climacteric symptoms, lipid metabolism, and hemostasis.
  
  
  METHODS
  In an open, multicenter study, 51 perimenopausal women were randomized to E2V/MPA and 50 to CE/MED. Assessment of climacteric complaints was performed at baseline and at months 1, 3, and 6. The effects on lipid and hemostatic variables were measured at baseline and at month 6. Quantitative data were analyzed using analysis of variance, the paired t-test or the chi2 Mantel-Hanszel test, where appropriate. RESILTS: Efficacy regarding treatment of climacteric symptoms was with E2V/MPA as good as with CE/MED, with a statistically significant reduction of most symptoms in both groups. After 6 months, total cholesterol and triglycerides had remained unchanged in both groups. High-density lipoprotein cholesterol showed no significant change with E2V/MPA, whereas an increase was noted in the CE/MED group (p<0.05). Low-density lipoprotein cholesterol was decreased with E2V/MPA (p<0.01) and was unchanged in the CE/MED group. Hemostatic parameters showed no significant changes after 6 months, with the exception of a decreased prothrombin time with E2V/MPA (p<0.05). Acceptability was excellent, expressed by the low incidence of treatment-related drop-outs in both groups.
  
  
  CONCLUSIONS
  E2V/MPA is a one tablet per day sequential HRT regimen, which is as effective and acceptable as hormone replacement therapy with CE/MED regarding treatment of climacteric symptoms. Neither preparation had negative effects on lipid metabolism and hemostatic variables.
authors.affiliation: Department of Obstetrics and Gynecology, University of Vienna, Austria.
authors.forename: C
authors.initials: C
authors.lastname: Egarter
authors.forename: P
authors.initials: P
authors.lastname: Geurts
authors.forename: E
authors.initials: E
authors.lastname: Boschitsch
authors.forename: P
authors.initials: P
authors.lastname: Speiser
authors.forename: J
authors.initials: J
authors.lastname: Huber
mesh_terms: D000328:Adult; D000367:Age Factors; D001835:Body Weight; D002979:Climacteric / Q000187:drug effects* / Q000378:metabolism; D004958:Estradiol / Q000031:analogs & derivatives* / Q000494:pharmacology; D015914:Estrogen Replacement Therapy / Q000379:methods*; D004966:Estrogens, Conjugated (USP) / Q000494:pharmacology*; D005260:Female; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D050356:Lipid Metabolism; D008524:Medrogestone / Q000494:pharmacology*; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology*; D008593:Menopause / Q000187:drug effects* / Q000378:metabolism; D008875:Middle Aged; D017698:Postmenopause / Q000187:drug effects* / Q000378:metabolism; D017697:Premenopause / Q000187:drug effects* / Q000378:metabolism; D045167:Progesterone Congeners / Q000494:pharmacology*
chemical_list: D004966:Estrogens, Conjugated (USP); D045167:Progesterone Congeners; D008524:Medrogestone; D004958:Estradiol; D017258:Medroxyprogesterone Acetate